HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Kim, Jinkyoung ^a   Jeong, Hoiseon ^b   Lee, Youngseok ^a   Kim, Chungyeul ^a   Kim, Hankyeom ^a   Kim, Aeree ^a  

^a Korea University College of Medicine   (South Korea)

^b Cheil General Hospital   (South Korea)

Author keywords

Breast cancer; EMT; ErbB3; Heregulin; Smad2; Small interfering RNA (siRNA); Transforming growth factor (TGF )

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBRONECTIN; HEREGULIN BETA1; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ERBB3 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL NUCLEUS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEOPLASM INVASIVENESS; NEUREGULIN-1; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84881128429     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-383     Document Type: Article

References (34)

1. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2(6):442-454. 10.1038/nrc822, 12189386.
2. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 hi/CD24 lo/-stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010, 15(2):235-252. 10.1007/s10911-010-9175-z, 20521089.
3. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132(14):3151-3161. 10.1242/dev.01907, 15983400.
4. Massagué J. TGF [beta] in cancer. Cell 2008, 134(2):215-230. 10.1016/j.cell.2008.07.001, 3512574, 18662538.
5. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res 2009, 19(2):156-172. 10.1038/cr.2009.5, 19153598.
6. Tsang KJ, Tsang D, Brown TN, Crowe DL. A novel dominant negative Smad2 mutation in a TGFβ resistant human carcinoma cell line. Anticancer Res 2002, 22(1A):13-19.
7. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010, 9(12):2363-2374. 10.4161/cc.9.12.12050, 20519943.
8. Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS One 2011, 6(10):e26514. 10.1371/journal.pone.0026514, 3197668, 22028892.
9. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002, 3(3):155-166.
10. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14(6):818-829. 10.1016/j.devcel.2008.05.009, 18539112.
11. Garratt AN. " To erb-B or not to erb-B..." Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol 2006, 41(2):215. 10.1016/j.yjmcc.2006.05.020, 16828796.
12. Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013, 73(16):OF1-OF12.
13. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284(1):14-30. 10.1016/S0014-4827(02)00102-7, 12648463.
14. Esper RM, Pankonin MS, Loeb JA. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Rev 2006, 51(2):161-175. 10.1016/j.brainresrev.2005.11.006, 16412517.
15. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006, 60(2):132-140. 10.1016/j.biopsych.2005.11.002, 16442083.
16. Panutsopulos D, Arvanitis DL, Tsatsanis C, Papalambros E, Sigala F, Spandidos DA. Expression of heregulin in human coronary atherosclerotic lesions. J Vasc Res 2005, 42(6):463-474. 10.1159/000088100, 16155362.
17. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006, 24(23):3735-3746. 10.1200/JCO.2005.04.3489, 16847284.
18. Dunn M, Sinha P, Campbell R, Blackburn E, Levinson N, Rampaul R, Bates T, Humphreys S, Gullick WJ. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol 2004, 203(2):672-680. 10.1002/path.1561, 15141382.
19. Cheng LS, Zha Z, Lang B, Liu J, Yao XB. Heregulin-β1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition. Cancer Lett 2009, 280(1):50-60. 10.1016/j.canlet.2009.02.007, 19269083.
20. Qureshi HY, Ricci G, Zafarullah M. Smad signaling pathway is a pivotal component of tissue inhibitor of metalloproteinases-3 regulation by transforming growth factor beta in human chondrocytes. Biochim Biophys Acta 2008, 1783(9):1605-1612. 10.1016/j.bbamcr.2008.04.005, 18471442.
21. Fu Y, O'Connor LM, Shepherd TG, Nachtigal MW. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor β-induced Smad signaling in human ovarian cancer cells. Biochem Biophys Res Commun 2003, 310(2):391-397. 10.1016/j.bbrc.2003.09.021, 14521923.
22. Nawshad A, Medici D, Liu CC, Hay ED. TGFβ3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. J Cell Sci 2007, 120(9):1646-1653. 10.1242/jcs.003129, 2659570, 17452626.
23. Jeong H, Ryu Y, An J, Lee Y, Kim A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 2012, 60:E87-E95. 10.1111/j.1365-2559.2012.04195.x, 22439911.
24. Marchini C, Montani M, Konstantinidou G, Orrù R, Mannucci S, Ramadori G, Gabrielli F, Baruzzi A, Berton G, Merigo F. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One 2010, 5(11):e14131. 10.1371/journal.pone.0014131, 2994727, 21152434.
25. Godde NJ, Galea RC, Elsum IA, Humbert PO. Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. J Mammary Gland Biol Neoplasia 2010, 15(2):149-168. 10.1007/s10911-010-9180-2, 20461450.
26. Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D, Mueller SC, Lupu R. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol 2000, 17(4):629.
27. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997, 276(5320):1848-1850. 10.1126/science.276.5320.1848, 9188528.
28. Hermanto U, Zong CS, Wang LH. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 2001, 20(51):7551. 10.1038/sj.onc.1204964, 11709727.
29. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003, 100(15):8933. 10.1073/pnas.1537685100, 166416, 12853564.
30. Kim A, Liu B, Ordonez-Ercan D, Alvarez K, Jones L, McKimmey C, Edgerton S, Yang XH, Thor A. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res 2005, 7(5):R708-R718. 10.1186/bcr1281, 1242139, 16168116.
31. Pearson G, Robinson F, Gibson TB, Xu B, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22(2):153-183. 10.1210/er.22.2.153, 11294822.
32. Castagnino P, Lorenzi MV, Yeh J, Breckenridge D, Sakata H, Munz B, Werner S, Bottaro DP. Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. Oncogene 2000, 19(5):640. 10.1038/sj.onc.1203357, 10698509.
33. Tsai M-S, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003, 22(5):761-768. 10.1038/sj.onc.1206130, 12569369.
34. Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee J, Robertson JF, Ellis IO, Nicholson RI. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 2007, 9(4):R50. 10.1186/bcr1754, 2206726, 17686159.